Professor and Chief of Pediatric Cardiac Surgery at the University of Maryland School of Medicine and an expert in heart failure both in children and adults. He performs over 200 cardiac surgery operations per year, has published over 100 peer-reviewed journal articles, and has a 10-member post-doctorate research laboratory funded partly through National Institute of Health grants.
Is a serial life sciences entrepreneur who has founded and successfully exited four companies including a structural heart start-up, a new treatment paradigm for respiratory patients and what was the largest sleep testing company in the U.S. Most recently, Mr Niland was President and CEO of Harpoon Medical, Inc. He co-founded Harpoon and successfully exited to Edwards Lifesciences in less than five years for $100M upfront (potentially $250M with milestones) with only $6.5M in dilutive capital, generating >100% IRR for investors. Prior to Harpoon, he founded Vapotherm (NYSE: VAPO) a non-invasive ventilation company that created the field of high flow nasal canula therapy for patients in respiratory distress. Vapotherm devices have been used to treat >1.5M patients since being founded in 1997 and the company recently went public on the New York Stock Exchange. Prior to Vapotherm, Mr. Niland successfully founded and exited two businesses, including National Sleep Technologies which was the largest sleep diagnostic and therapy company in the US when it was acquired by Vital Signs. Mr. Niland also holds 16 patents.
Dr. Rasmussen has more than 25 years of experience in the pharmaceutical and biotech industries. Prior to joining NeoProgen, Dr. Rasmussen was the CMO at ZS Pharma, where he worked from 2010 to 2016. Prior to joining ZS Pharma, he was the President and CEO of Rasmussen Biotech & Pharma Consulting. Dr. Rasmussen has held the positions of Corporate Vice President, Head of Clinical Development, Medical & Regulatory Affairs at Novo Nordisk, and CMO, for Nabi Biopharmaceuticals and GenVec. He was the Senior Vice President for Clinical Research and Regulatory Affairs at British Biotech and Global Study Director for Cardiovascular Drug Development at Pfizer Central Research. Dr. Rasmussen has led numerous global development programs and regulatory filings worldwide, including INDs, clinical trial applications (CTAs), NDAs, supplemental new drug applications (sNDAs), biologic license applications (BLAs), and MMA filings. He has published over 150 peer-reviewed papers in the therapeutic areas of Nephrology, Cardiology, Ophthalmology, Gastroenterology and Diabetes.
Dr. Rasmussen received his MD and PhD from the University of Copenhagen, Denmark, and is trained in Internal Medicine and Cardiology.
Pharmaceuticals executive with substantial leadership and management experience both in the academic and pharmaceutical industry settings. Directed a laboratory of up to 15 students, postdoctoral, and clinical fellows in innovative research that led to important findings published in high-impact, peer-reviewed journals. Led a variety of drug discovery teams, ranging in size from 16 to 245 colleagues, across diverse geographic locations, disciplines, and functional interfaces. Headed the delivery of CVMD strategic objectives managing a portfolio of programs in multiple therapeutic areas, driving identification and delivery of innovative new programs, in-licensing, partnering, and collaborations with academic groups, venture and non-profit research organizations, biotech and big-pharma companies.